XTL Biopharmaceuticals Ltd. (XTLB)
 NASDAQ: XTLB · Real-Time Price · USD
 1.080
 -0.110 (-9.24%)
  At close: Oct 30, 2025, 4:00 PM EDT
1.090
 +0.010 (0.93%)
  After-hours: Oct 30, 2025, 6:44 PM EDT
XTL Biopharmaceuticals Revenue
In the year 2024, XTL Biopharmaceuticals had annual revenue of $451.00K. XTL Biopharmaceuticals had revenue of $405.00K in the quarter ending December 31, 2024.
Revenue (ttm) 
 $451.00K
Revenue Growth 
 n/a
P/S Ratio 
 22.83
Revenue / Employee 
 $45,100
Employees 
 10
Market Cap 
10.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 451.00K | - | - | 
| Dec 31, 2023 | - | - | - | 
| Dec 31, 2022 | - | - | - | 
| Dec 31, 2021 | - | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 422.82B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 55.19B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
XTLB News
- 7 months ago - XTL Names Mr. Noam Band as its New Chief Executive Officer - GlobeNewsWire
- 1 year ago - XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million - GlobeNewsWire
- 1 year ago - XTL Entered Definitive Agreement to Acquire The Social Proxy - GlobeNewsWire
- 1 year ago - XTL To Aquire The Social Proxy - GlobeNewsWire
- 2 years ago - XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel - GlobeNewsWire
- 2 years ago - XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewsWire
- 4 years ago - Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting - PRNewsWire